Feb 3 (Reuters) - Merck (N:MRK) MRK.N :
* Receives approval of ZEPATIER (elbasvir/grazoprevir) in Canada for the
treatment of chronic Hepatitis C for patients with Genotype 1, 3, or 4
infection following priority review
* Says ZEPATIER achieves high cure rates of 95-98% in broad range of patients
with chronic Hepatitis C infection
* Source text for Eikon Further company coverage MRK.N